Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05570955
NA

Deucravacitinib Adherence Study

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2023-07-24

Completion Date

2027-03

Last Updated

2026-03-31

Healthy Volunteers

No

Conditions

Interventions

BEHAVIORAL

Text reminder

weekly text to remind use of drug

Locations (1)

Wake Forest University Health Sciences Department of Dermatology

Winston-Salem, North Carolina, United States